Compare Harmony Gold Mining Co. (HMY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs BIO-TECHNE Corp — how do they compare? Harmony Gold Mining Co. trades at $19.68 (market cap $12.33B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Harmony Gold Mining Co. and BIO-TECHNE Corp are close in size by market cap, and Harmony Gold Mining Co. pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| HMY | TECH | |
|---|---|---|
Market Cap | $12.33B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $72.29 |
52-Week Low | $12.61 | $43.31 |
Enterprise Value | $12.68B | $11.32B |
Dividend Yield | 2.05% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $19.71, up 9.2% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2024 revenue of $61.38B, net income of $8.59B, and improving profit margins. Recent earnings show mixed results with a Q4 2025 miss but strong operational cash flow growth. The stock is transitioning from pure gold mining to gold-copper production, with copper segment expansion underway.
HMY presents a compelling value case with attractive valuation ratios (P/E 12.49, EV/EBITDA 6.45) and strong profitability metrics (ROE 32.32%). However, analyst sentiment remains cautious with 70% hold ratings, and technical indicators show overbought conditions with RSI above 80. Key risks include gold price volatility, Fed policy impacts, and execution challenges in copper diversification.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
